Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209365 | 0.85 | HTR6 (0.70) | HTR6DRD3DRD2CYP3A4HTR2A | |
| SCHEMBL3212926 | 0.84 | HTR6 (0.74) | HTR6CYP3A4HTR2AHTR2C | |
| SCHEMBL5771847 | 0.80 | HTR6 (0.57) | HTR6DRD3DRD2CYP3A4ALDH1A1 | |
| SCHEMBL3198751 | 0.76 | HTR6 (0.68) | HTR6MET | |
| SCHEMBL3188736 | 0.75 | HTR6 (0.48) | HTR6DRD3DRD2CYP3A4MET | |
| SCHEMBL3212729 | 0.73 | HTR6 (0.48) | HTR6DRD3DRD2CYP3A4MET | |
| SCHEMBL3213137 | 0.73 | HTR6 (0.46) | HTR6DRD3DRD2CYP3A4MET | |
| SCHEMBL5774777 | 0.71 | HTR6 (0.56) | HTR6DRD3DRD2KLK7L3MBTL1 | |
| SCHEMBL4508580 | 0.70 | HTR6 (0.49) | HTR6DRD3DRD2FABP4 | |
| SCHEMBL14216253 | 0.70 | HTR6 (0.72) | HTR6DRD3DRD2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671079-B2 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-03-02 | — | — | US | claimed |
| US-7288561-B2 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-30 | — | — | US | claimed |
| EP-1682502-A1 | SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005047252-A1 | SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101596-A1 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-12 | — | — | US | claimed |
| US-7671079-B2 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| US-7288561-B2 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1682502-A1 | SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047252-A1 | SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101596-A1 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | HTR6 1/4885DRD3 274/4885DRD2 142/4885 |
| US-20050101596-A1 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | HTR6 1/4885DRD3 274/4885DRD2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.